Navigation Links
GENFIT: Strong U.S. Exposure for Its Biomarker Activity
Date:1/6/2011

LILLE, France and CAMBRIDGE, Mass., Jan. 6, 2011 /PRNewswire/ -- GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announced its presence at two U.S. events: the 28th J.P. Morgan Healthcare Conference (from January 11th to 14th, 2011) and the Biotech Showcase (from January 10th to 12th, 2011).

At these events, the Company will give a progress update on its research programs, in particular those dedicated to the theranostic field, that are based on GENFIT's proprietary microparticle capture and characterization technologies for the identification of novel biomarkers:

- The BMGFT01 program, through a translational approach combining specific preclinical models and clinical cohorts of patients at high cardiovascular risk, is dedicated to the discovery of early markers of atherosclerosis and vulnerable plaque via the analysis of plasmatic microparticle signatures.

-  The BMGFT02 program, in the field of type 2 diabetes and its early stages, aims to identify novel biomarkers of pancreatic beta cell dysfunction, in particular through two major clinical studies (DECODIAB and ABOS) involving the longitudinal follow-up of more than 1000 patients.

Jean-Francois Mouney, Chairman of GENFIT's Management Board, stated: "At a time of intense negotiations for our leading drug candidate GFT505, we are proud to present the significant progress that GENFIT has made on its programs linked to the detection of early biomarkers of diabetes and atherosclerosis. For the past two years, GENFIT has been working on the development of a breakthrough technology in this domain. This technology will provide, on the one hand, a rapid, targeted, and predictive follow-up of the efficacy of new treatments for certain metabolic pathologies, and, on the other hand, new diagnostic solutions for these same diseases at very early stages. In this context, our newsflow in the biomarker area will be particularly active this year."

About GENFIT:GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...).  GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies (SANOFI-AVENTIS, SERVIER,...), to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase II.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 100 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Items in this press release may contain forward-looking statements involving risks and uncertainties.  The Company's actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company's prospectus.  This press release has been prepared in both French and English languages.  In the event of any differences between the two texts, the French language version shall supersede.Contacts:GENFITJean-Francois Mouney – CEO & Chairman of the Management Board+33 (0)3 2016 4000MILESTONES – Press RelationsBruno Arabian+33 (0)1 75 44 87 40 / +33 (0)6 87 88 47 26 – barabian@milestones.frRusso PartnersMartina Schwarzkopf, Ph.D.+1 212 845-4292 / +1 347 591 8785 - martina.schwarzkopf@russopartnersllc.com
'/>"/>

SOURCE GENFIT
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China Medicine Announces Strong Second Quarter 2008 Results
2. Fufeng Announces 2008 Interim Results With Strong Sign of Recovery
3. Dry adhesive based on carbon nanotubes gets stronger, with directional gripping ability
4. Senetek Affirms Strong Financial Position
5. Strong elasticity size effects in ZnO nanowires
6. Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan
7. Cephalon Reports Another Strong Quarter
8. Shires New Product Portfolio Delivers Strong Quarterly Performance
9. OmniComm Systems, Inc. Is Fueled by Another Strong Quarter Delivering Electronic Data Capture (EDC) Solutions & Services
10. Varian, Inc. Reports Strong Fourth Quarter 2008 Results
11. ACORN CRO Continues Growth in Strong Third Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017  UBM and the ... announce their extended partnership and the third annual Massachusetts ... by the 21 st Annual MassMEDIC Conference ... place May 3-4, 2017. MassMEDIC ... Association (ADVAMED) President and CEO, Scott Whitaker ...
(Date:3/22/2017)... , March 22, 2017 Oramed Pharmaceuticals ... www.oramed.com ), a clinical-stage ... drug delivery systems, announced today that Dr. ... deliver a presentation titled, "Oral Insulin for Diabetes ... Cambridge Healthtech Institute,s Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference ...
(Date:3/22/2017)... , March 22, 2017 The ... states a research report by Transparency Market Research (TMR). ... Amgen Inc., and AbbVie Inc., accounted for a share ... prominent players in this market are focusing aggressively on ... portfolio, which is likely to lead to market consolidation ...
(Date:3/22/2017)... 22, 2017 /PRNewswire/ - FACIT announced a seed ... "Propellon"), a start-up created by FACIT focused on ... investment, combined with non-dilutive capital, achieves a targeted ... funding enables Propellon to accelerate the nomination of ... financing and/or entering a strategic partnership for clinical ...
Breaking Biology Technology:
(Date:3/6/2017)... , March 6, 2017 Mintigo ... technology, today announced Predictive Sales Coach TM , ... actionable sales intelligence into Salesforce. This unique AI ... their sales organizations with deep knowledge of their ... for intelligent engagement. Predictive Sales Coach extends Mintigo,s ...
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ... Iris-Scan, wird seine erstklassige biometrische Lösung zur ... 835 mit X16 LTE auf dem Mobile ... März) am Qualcomm-Stand in Halle 3, Stand ... beinhaltet die Sicherheitsplattform Qualcomm Haven™ – eine ...
Breaking Biology News(10 mins):